

REMARKS

In an Advisory Action dated March 25, 2003, it is noted that the After Final Amendment that was filed in this case on March 5, 2003 was not entered, because the proposed amendment to claim 7 would broaden the scope of claim 5, from which claim 7 indirectly depends, thus raising a new issue. In particular, the amendment to claim 7 proposed in the March 5, 2003 submission includes the words "further comprising," which the Examiner notes opens the scope of claim 5, which includes the words "consisting essentially of." The proposed amendment to claim 7 was not intended to allow the inclusion of additional steps in the method of claim 5, but rather was intended to show that the induced immune response also included a Th2 immune response. To clarify this matter, claim 7 has been amended to remove the language "further comprising."

Applicants respectfully submit that, in view of the remaining Amendments and Remarks made in the March 5, 2003 submission, the claims are in condition for allowance, and such action is requested. If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: July 7, 2003

Susan M. Michaud
Susan M. Michaud, Ph.D.
Reg. No. 42,885

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045
06132.054001 reply after advisory action.doc


21559
PATENT TRADEMARK OFFICE

Version of Amendment with Markings to Show Changes Made

Claim 7 has been amended as follows.

7. (Amended four times) The method of Claim 6, wherein a Th1-type immune response
and [further comprising induction of] a Th2-type immune response are induced and [, wherein]
the immune response of said mammal is characterized by either (i) a ratio of the ELISA
IgG2a:IgG1 titers greater than or equal to 1:100, or (ii) a ratio of the ELISA IgG2a:IgA titers
greater than or equal to 1:100.